logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2018 – Is neoadjuvant erlotinib ready for centre stage in early mutated non­-small­ cell lung cancer?

A phase 2 study from China demonstrated superiority in progression-free survival for erlotinib over gemcitabine plus cisplatin in the neoadjuvant/adjuvant setting of stage IIIA-N2 EGFR mutated non­-small­ cell lung cancer.